Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch-Over, Open-Label Study of HPN-100 in Pediatric Subjects Under 6 Years With Urea Cycle Disorders
2014-003249-82Phase 2
- Sponsor
- Hyperion Therapeutics, Inc.
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycerol phenylbutyrate in urea cycle disorder (UCD), sponsored by Hyperion Therapeutics, Inc. Primary endpoint: Rate of adverse events.
02
Drugs
glycerol phenylbutyrate
03
Conditions
urea cycle disorder (UCD)
Beyond the preview
Go deeper on 2014-003249-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003249-82.